XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net loss $ (19,694,697) $ (30,469,871)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 371,367 424,473  
Amortization of operating lease right-of-use assets 372,083 335,257  
Change in fair value of common stock warrant liability (3,712,872) 0  
Non-cash stock-based compensation 1,399,349 2,525,433  
Non-cash interest on senior convertible notes 0 (355,654)  
Amortization of discounts on investments (386) (684,651)  
Loss on sales of short-term investments 482 691,168  
(Gain) loss on equity investment in affiliated entity (695,131) 126,018  
Net unrealized gain on available-for-sale equity securities (140,234) (500,877)  
Changes in operating assets and liabilities:      
Accounts receivable from affiliated entity (111,181) (145,854)  
Prepaid expenses and other current assets 295,797 1,897,016  
Accounts payable and accrued expenses, including due to affiliated entity (4,161,751) (3,160,238)  
Accrued clinical trial expenses (202,623) 657,104  
Operating lease right-of-use assets and liabilities, net (594,230) (11,791)  
Grant funding liability, including from affiliated entity 0 (87,489)  
Net cash used in operating activities (26,874,027) (28,759,956)  
Cash flows from investing activities:      
Purchases of investments 0 (9,751,047)  
Proceeds from sale or maturity of investments 7,620 55,169,260  
Purchases of capital assets (59,373) (35,578)  
Net cash (used in) provided by investing activities (51,753) 45,382,635  
Cash flows from financing activities:      
Repayment of convertible senior notes 0 (16,415,000)  
Proceeds from issuance of common stock, net of issuance costs 1,102,149 5,225,133  
Taxes paid related to net share settlement of equity awards (74,219) (174,248)  
Net cash provided by (used in) financing activities 1,027,930 (11,364,115)  
Effect of exchange rate changes on cash and cash equivalents 0 32,403  
(Decrease) Increase in cash and cash equivalents (25,897,850) 5,290,967  
Cash and cash equivalents, beginning of period 65,813,297 14,310,862 $ 14,310,862
Cash and cash equivalents, end of period 39,915,447 19,601,829 $ 65,813,297
Supplemental disclosures:      
Amounts accrued for purchases of fixed assets 0 442,976  
Interest paid $ 0 $ 533,487